Verastem, Inc. (VSTM) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Current obligations | 78.13M USD | Liabilities, Current |
| Cash and equivalents | 136.35M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | 2.40M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $78.13M | $136.35M | (m) | (m) | $2.40M | (m) |
| 2026-03-31 | (m) | $66.84M | $165.55M | (m) | (m) | $2.29M | (m) |
| 2025-12-31 | (m) | $72.27M | $204.99M | (m) | (m) | $1.83M | (m) |
| 2025-09-30 | (m) | $59.71M | $137.71M | (m) | (m) | $1.79M | (m) |
| 2025-06-30 | (m) | $50.36M | $164.32M | (m) | (m) | $1.17M | (m) |
| 2025-03-31 | (m) | $35.62M | $117.57M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $30.97M | $88.82M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $37.37M | $113.17M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $30.35M | $83.37M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $26.73M | $81.32M | $28.81M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $26.38M | $77.91M | $59.22M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $23.81M | $94.99M | $70.68M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $20.79M | $183.09M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $22.36M | $97.26M | $13.94M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $21.66M | $74.93M | $12.96M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $21.87M | $78.17M | $25.81M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $20.09M | $63.95M | $30.36M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $16.89M | $46.69M | $59.59M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $18.59M | $21.25M | $79.00M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $13.54M | $24.31M | $79.10M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $12.74M | $24.97M | $83.16M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $11.84M | $35.51M | $85.58M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $17.09M | $67.78M | $73.44M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $37.68M | $170.47M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $28.78M | $125.33M | (m) | (m) | $6.32M | (m) |
| 2020-03-31 | (m) | $25.73M | $135.06M | (m) | (m) | $4.37M | (m) |
| 2019-12-31 | (m) | $29.89M | $43.51M | $31.99M | (m) | $3.10M | (m) |
| 2019-09-30 | (m) | $30.51M | $103.32M | $56.91M | (m) | $478.00K | (m) |
| 2019-06-30 | (m) | $31.20M | $113.08M | $74.17M | (m) | $294.00K | (m) |
| 2019-03-31 | (m) | $28.62M | $91.53M | $120.13M | (m) | $306.00K | (m) |
| 2018-12-31 | (m) | $37.08M | $129.87M | $119.79M | (m) | $327.00K | (m) |
| 2018-09-30 | (m) | $53.44M | $130.73M | $14.91M | (m) | $131.00K | (m) |
| 2018-06-30 | (m) | $22.13M | $168.69M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $14.85M | $64.22M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $17.13M | $82.18M | $4.50M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $19.62M | $51.27M | $8.99M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $11.07M | $27.58M | $30.34M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $13.23M | $28.18M | $44.39M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $10.99M | $32.35M | $48.55M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $6.22M | $37.27M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $5.92M | $39.56M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $6.12M | $15.15M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $10.11M | $24.87M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $10.86M | $19.83M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $9.84M | $35.17M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $9.46M | $30.13M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $9.20M | $33.90M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $8.38M | $20.56M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $7.87M | $22.39M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $6.39M | $13.24M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $7.80M | $18.89M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $5.71M | $22.64M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $5.24M | $13.88M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $3.36M | $28.25M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $2.40M | $10.10M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $3.15M | $11.13M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $3.21M | $15.75M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $2.94M | $25.47M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $3.15M | $20.95M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | $41.42M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $14.16M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $2.72M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $3.58M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |